Related Experiment Video

Updated: Aug 13, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

Subgroup analyses in therapeutic cardiovascular clinical trials: are most of them misleading?

Adrián V Hernández1, Eric Boersma, Gordon D Murray

  • 1Center for Clinical Decision Sciences, Department of Public Health, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands. a.hernandez@erasmusmc.nl

American Heart Journal
|January 31, 2006
PubMed

Insights

Subgroup analyses in cardiovascular trials often lack proper prespecification and statistical testing. Improved reporting is crucial to prevent misleading treatment decisions based on secondary findings.

Area of Science:

  • Cardiology
  • Clinical Trials
  • Biostatistics

Background:

  • Randomized clinical trials (RCTs) guide cardiovascular treatment decisions.
  • Subgroup analysis interpretation in these trials requires scrutiny.

Purpose of the Study:

  • To assess the appropriateness of subgroup analysis use and interpretation in cardiovascular RCTs.
  • To identify shortcomings in reporting practices.

Main Methods:

  • Reviewed 63 phase 3 cardiovascular RCTs (≥100 patients) from major journals (2002, 2004).
  • Evaluated subgroup analysis reporting: prespecification, number, interaction tests, significance, and emphasis.
  • Analyzed reporting differences by sample size, trial outcome, and CONSORT adherence.

Main Results:

  • 39/63 RCTs reported subgroup analyses; 26 had >5 subgroups.
  • No RCT was powered for subgroup effects; only 14 had fully prespecified subgroups.
  • 11 RCTs used interaction tests; 21 claimed significant subgroups, 15 emphasized them over overall results.

Conclusions:

  • Cardiovascular RCT subgroup analyses frequently lack prespecification and appropriate statistical testing.
  • Emphasis on subgroup findings without proper methodology can mislead clinical treatment decisions.
  • Substantial improvements in reporting subgroup analyses are necessary.
Abstract

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...